HC Wainwright Reiterates “Buy” Rating for AEterna Zentaris (AEZS)

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research report issued to clients and investors on Wednesday. They currently have a $3.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price objective would suggest a potential upside of 18.11% from the stock’s previous close.

The analysts wrote, “We maintain our Buy rating of AEZS and adjust our 12-month price target to $3.00 per share. We derived our price target based on the average of two valuation methods: (1) price-sales multiple using 8x 2025 sales estimate discounted at 18%; and (2) price-earnings multiple using 25x 2025 earnings estimate also discounted at 18%.””

Several other equities research analysts have also issued reports on the stock. ValuEngine lowered shares of AEterna Zentaris from a “sell” rating to a “strong sell” rating in a research note on Monday, September 17th. Zacks Investment Research upgraded shares of AEterna Zentaris from a “hold” rating to a “buy” rating and set a $1.75 price target on the stock in a research note on Tuesday, October 9th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $3.25.

Shares of AEZS stock opened at $2.54 on Wednesday. AEterna Zentaris has a 1 year low of $1.12 and a 1 year high of $3.25. The firm has a market capitalization of $39.62 million, a price-to-earnings ratio of -1.88 and a beta of 0.75.

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last issued its quarterly earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.10. AEterna Zentaris had a net margin of 34.40% and a return on equity of 83.33%. The firm had revenue of $0.66 million for the quarter. Equities research analysts anticipate that AEterna Zentaris will post 0.05 earnings per share for the current fiscal year.

An institutional investor recently bought a new position in AEterna Zentaris stock. Virtu Financial LLC acquired a new position in shares of AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 51,028 shares of the biopharmaceutical company’s stock, valued at approximately $101,000. Virtu Financial LLC owned about 0.31% of AEterna Zentaris at the end of the most recent reporting period. 2.95% of the stock is currently owned by hedge funds and other institutional investors.

AEterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.

Featured Story: Fundamental Analysis – How It Helps Investors

Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply